Clinical trials: Rituximab, completed
Diffuse Large B Cell Lymphoma
Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma
This is a phase I/II open label, multi-center study of azacytidine in combination with standard RCHOP therapy in patients with DLBCL.
- Trial name
- NCT01004991
- Testing
- rituximab, cyclophosphamide, vincristine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Weill Medical College of Cornell University
Mantle Cell Lymphoma
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of ibrutinib given in combination with bendamustine and rituximab in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.
- Trial name
- NCT01776840
- Testing
- Bendamustine, Rituximab, Ibrutinib
- Where
- 201 sites in United States, Argentina and 26 more
- Volunteers
- 523 people
- Sponsor
- Janssen Research & Development, LLC
Lymphoma
S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find cancer cells and carry cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00107380
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 78 sites in United States
- Volunteers
- 86 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma
A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma
This randomized, open-label study will compare the efficacy and safety of MabThera/Rituxan (rituximab) alone, and in combination with Roferon-A (interferon alfa-2a) in patients with follicular or other CD20+ low-grade lymphoma.
- Trial name
- NCT01609010
- Testing
- rituximab, interferon-a-2a
- Where
- 31 sites in Denmark, Norway and 1 more
- Volunteers
- 313 people
- Sponsor
- Hoffmann-La Roche
Exposure to Hepatitis B Virus
Risk of Hepatitis B Reactivation in Patients With Prior HBV Exposure Undergoing Rituximab-containing Chemotherapy: A Prospective Study
The purpose of this study is to determine whether preemptive nucleoside analogue therapy or regular virologic monitoring is the preferred method in management patients with prior exposure to hepatitis B vius (HBV) and undergoing…
- Trial name
- NCT01502397
- Where
- Hong Kong
- Volunteers
- 70 people
- Sponsor
- The University of Hong Kong
Rheumatoid Arthritis
A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis
WA16291 is a Phase IIa "proof-of-concept" study. The primary objective of this study is to determine the safety and efficacy of rituximab (a B cell depleting chimeric monoclonal antibody) used either as monotherapy or in…
- Trial name
- NCT02693210
- Testing
- Cyclophosphamide, Methotrexate
- Where
- 33 sites in Australia, Belgium and 9 more
- Volunteers
- 161 people
- Sponsor
- Hoffmann-La Roche
Arthritis, Rheumatoid
A Study To Describe The Use Of Tofacitinib After Use Of Rituximab In Patients With Rheumatoid Arthritis In A Real-World Setting
This study is to characterize the use of tofacitinib after use of rituximab in patients with Rheumatoid Arthritis in a real-world setting.
- Trial name
- NCT05487703
- Where
- Morocco
- Volunteers
- 318 people
- Sponsor
- Pfizer
Leukemia, Lymphoma
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
The goal of this clinical research study is to find the highest tolerated dose of gemcitabine that can be given with busulfan and melphalan. The safety of this drug combination will also be studied.
- Conditions
- Leukemia, Lymphoma, Myeloma
- Trial name
- NCT00410982
- Testing
- Busulfan, Gemcitabine, Melphalan
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- M.D. Anderson Cancer Center
Rheumatoid Arthritis
Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy
That anti-TNF therapy and rituximab therapy are equally effective in treating patients with rheumatoid arthritis who meet the eligibility criteria for biologic therapy in the British Society for Rheumatology guidelines, and have…
- Trial name
- ORBIT (NCT01021735)
- Testing
- etanercept or adalimumab, Rituximab
- Where
- 8 sites in United Kingdom
- Volunteers
- 302 people
- Sponsor
- University of Glasgow
Lymphoma
Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
RATIONALE: Cellular adoptive immunotherapy uses a person's white blood cells that are treated in the laboratory to stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00182650
- Testing
- aldesleukin, rituximab, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- City of Hope Medical Center
Childhood Idiopathic Nephrotic Syndrome
Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood
Background Idiopathic nephrotic syndrome is a rare disease beginning during childhood and treated with immunosuppressants (i.e. steroids, mycophenolate mofetil, cyclophosphamide, cyclosporine).
- Trial name
- NEPHRUTIX (NCT01268033)
- Testing
- Rituximab
- Where
- 24 sites in Belgium, France
- Volunteers
- 26 people
- Sponsor
- University Hospital, Limoges
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.
This single arm study will evaluate the safety and efficacy of MabThera in participants with active rheumatoid arthritis who have had an inadequate response to prior treatment with DMARDs and/or anti-TNF alpha agent.
- Trial name
- NCT00503425
- Testing
- Rituximab [MabThera/Rituxan]
- Where
- 16 sites in Israel
- Volunteers
- 215 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Non-Hodgkin
Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients
This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma
- Trial name
- NIVEAU (NCT03366272)
- Testing
- Nivolumab, Rituximab, Gemcitabine
- Where
- 77 sites in Austria, Belgium and 6 more
- Volunteers
- 348 people
- Sponsor
- Universität des Saarlandes
Lymphoma
Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, can block cancer cells in different ways.
- Trial name
- NCT01334502
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Early and Severe Systemic Sclerosis
A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab
Rituximab 1000 mg i.v. will be given on day 1 and 15, week 26 - 28, together with a corticosteroid regimen consisting of methylprednisolone 100 mg i.v. 30 minutes prior to both infusions.
- Trial name
- NCT00379431
- Testing
- Administration of rituximab and methylprednisolone
- Where
- 4 sites in Belgium
- Volunteers
- 9 people
- Sponsor
- University Hospital, Ghent
Pemphigus
Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab
The purpose of this study is to study the midterm clinical evaluation, biological parameters and immune reconstitution after Rituximab treatment for Pemphigus.
- Trial name
- Suiviritux (NCT01299857)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Rouen
Thrombotic Thrombocytopenic Purpura
A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Primary Objective: To evaluate the effect of caplacizumab on prevention of recurrence of aTTP (proportion of participants with a recurrence of aTTP) during the overall study period.
- Trial name
- NCT04074187
- Testing
- Caplacizumab (ALX-0081), Plasma exchange (PE), Corticosteroid treatment (Methylprednisolone or prednisolone)
- Where
- 12 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Sanofi
Lymphoma, Malignant
Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma
Combination of involved field radiotherapy for the control of macroscopic disease and CD20 antibody Rituximab for the control of microscopic remainders in other regions in patients with early stage nodal follicular lymphoma…
- Trial name
- MIR (NCT00509184)
- Testing
- Rituximab
- Where
- 17 sites in Germany
- Volunteers
- 85 people
- Sponsor
- Klaus Herfarth, MD
Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)
Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma
In spite of high initial response rate after a first line treatment by R-polychemotherapy, cutaneous but also extra-cutaneous recurrences occur after 2 years in about half of the patients with PCBCL-LT.
- Trial name
- REV-LEG (NCT01556035)
- Testing
- Lenalidomide
- Where
- 24 sites in France
- Volunteers
- 19 people
- Sponsor
- University Hospital, Bordeaux
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
The purpose of this research study is to evaluate a new investigational drug, TAK-659, given in combination with standard chemotherapy, for the treatment of Diffuse Large B-cell Lymphoma (DLBCL).
- Conditions
- Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT03742258
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.